Bardoxolone methyl (RTA 402) | ≥99%(HPLC) | IκB/IKK inhibitor | AdooQ®
Bardoxolone methyl: drug development for diabetic kidney disease | SpringerLink
Design and Synthesis of Irreversible Analogues of Bardoxolone Methyl for the Identification of Pharmacologically Relevant Targets and Interaction Sites | Journal of Medicinal Chemistry
Derivative of Bardoxolone Methyl, dh404, in an Inverse Dose-Dependent Manner Lessens Diabetes-Associated Atherosclerosis and Imp
Bardoxolone Methyl and a Related Triterpenoid Downregulate cMyc Expression in Leukemia Cells | Molecular Pharmacology
Antioxidants | Free Full-Text | Pharmacotherapy against Oxidative Stress in Chronic Kidney Disease: Promising Small Molecule Natural Products Targeting Nrf2-HO-1 Signaling | HTML
Targeting crosstalk between Nrf-2, NF-κB and androgen receptor signaling in prostate cancer
Cancers | Free Full-Text | Targeting Crosstalk between Nrf-2, NF-κB and Androgen Receptor Signaling in Prostate Cancer | HTML
Bardoxolone methyl - Wikipedia
Bardoxolone conjugation enables targeted protein degradation of BRD4 | Scientific Reports
Bardoxolone Methyl Decreases Megalin and Activates Nrf2 in the Kidney | American Society of Nephrology
Can Activation of NRF2 Be a Strategy against COVID-19?: Trends in Pharmacological Sciences
Schematic image of potential mechanism by which bardoxolone methyl... | Download Scientific Diagram
Bardoxolone methyl: drug development for diabetic kidney disease | SpringerLink
Bardoxolone - an overview | ScienceDirect Topics
Increased albuminuria in bardoxolone methyl–treated type 2 diabetes patients: mere reflection of eGFR improvement? - Kidney International
NF-kB Signaling Pathway products from Selleck Chemicals
Bardoxolone Methyl Decreases Megalin and Activates Nrf2 in the Kidney | American Society of Nephrology
Reata Pharmaceuticals Inc. - Our Science - Our Technologies - Nrf2 Activators
Risk Factors for Heart Failure in Patients With Type 2 Diabetes Mellitus and Stage 4 Chronic Kidney Disease Treated With Bardoxolone Methyl - Journal of Cardiac Failure
Bardoxolone Methyl and Kidney Function in CKD with Type 2 Diabetes | NEJM
Bardoxolone Methyl | ≥99%(HPLC) | Selleck | IκB/IKK inhibitor
Bardoxolone methyl | 218600-53-4
